Cargando…

Impact of rituximab on humoral response to SARS-CoV-2 vaccination in previously vaccinated patients with autoimmune diseases

SARS-CoV-2 infection is more severe in patients undergoing rituximab (RTX) treatment. Humoral response to vaccination is severely impaired in patients already treated with RTX, but data on antibody persistence in patients initiating RTX are lacking. We evaluated the impact of RTX initiation on humor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oliosi, E., Flahault, A., Charre, C., Veyer, D., Combier, A., Lafont, E., Karras, A., Mouthon, L., Avouac, J., Terrier, B., Hadjadj, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224652/ https://www.ncbi.nlm.nih.gov/pubmed/37243801 http://dx.doi.org/10.1007/s10067-023-06638-0

Ejemplares similares

Impact de l’initiation d’un traitement par rituximab sur la réponse humoral à la vaccination anti-SARS-CoV-2 chez des patients ayant une maladie auto-immune et préalablement vaccinés
por: Oliosi, E., et al.
Publicado: (2022)

Fatal Measles Virus Infection After Rituximab-Containing Chemotherapy in a Previously Vaccinated Patient
por: Jent, Philipp, et al.
Publicado: (2018)

Facteurs de risque de réponse insuffisante à la vaccination contre la COVID-19 chez les patients traités par rituximab
por: Avouac, J., et al.
Publicado: (2021)

Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses
por: Bitoun, Samuel, et al.
Publicado: (2022)

A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE
por: van Dam, Laura S, et al.
Publicado: (2020)

Previous Infection with SARS-CoV-2 Correlates with Increased Protective Humoral Responses after a Single Dose of an Inactivated COVID-19 Vaccine
por: Bagno, Flávia F., et al.
Publicado: (2022)

Sustained complete B cell depletion is associated with rituximab efficacy in connective tissue disorders-associated interstitial lung disease
por: Al Tabaa, Omar, et al.
Publicado: (2023)

Pneumococcal vaccine/rituximab: Acquired humoral deficiency leading to infections and pneumococcal vaccine failure: case report
Publicado: (2021)

Antibiotic Therapy Does Not Alter the Humoral Response to Vaccination for Porcine Circovirus 2 in Weaned Pigs
por: Fogle, Jonathan E., et al.
Publicado: (2019)

Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis
por: van der Togt, Céleste J T, et al.
Publicado: (2022)

B-lymphocyte reconstitution after repeated rituximab treatment in a child with steroid-dependent autoimmune hemolytic anemia
por: van der Linde, Annelieke A.A., et al.
Publicado: (2011)

Acute hepatitis with autoimmune features after COVID-19 vaccine: coincidence or vaccine-induced phenomenon?
por: Pinazo-Bandera, José M, et al.
Publicado: (2022)

French Vasculitis Study Group recommendations for the management of COVID-19 vaccination and prophylaxis in patients with systemic vasculitis
por: Puéchal, Xavier, et al.
Publicado: (2022)

Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis
por: Puéchal, Xavier, et al.
Publicado: (2022)

SH2D1A Regulates T-dependent Humoral Autoimmunity
por: Hron, Jonathan D., et al.
Publicado: (2004)

Rituximab: Humoral immunodeficiency: case report
Publicado: (2021)

Levels of Produced Antibodies after Vaccination with mRNA Vaccine; Effect of Previous Infection with SARS-CoV-2
por: Konstantinidis, Theocharis G., et al.
Publicado: (2021)

Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination
por: Puro, Vincenzo, et al.
Publicado: (2021)

Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Thietart, Sara, et al.
Publicado: (2022)

Immunogénicité du vaccin BNT162b2 chez les patients avec maladies auto-immunes sous immunosuppresseurs
por: Hadjadj, J., et al.
Publicado: (2021)

Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine
por: Pira, Anna, et al.
Publicado: (2023)

Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab
por: Felten, Renaud, et al.
Publicado: (2022)

Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease
por: Kappelman, Michael D., et al.
Publicado: (2021)

The Kinetics of Humoral and Cellular Responses after the Booster Dose of COVID-19 Vaccine in Inflammatory Arthritis Patients
por: Wroński, Jakub, et al.
Publicado: (2023)

Exacerbation of Chronic Cutaneous Lupus Erythematosus Triggered by Vaccine Against COVID-19
por: Souza, E.N., et al.
Publicado: (2022)

A Case of Autoimmune Hepatitis Treated with Rituximab
por: Barth, E., et al.
Publicado: (2010)

Infections sévères à entérovirus chez les patients traités par rituximab pour une maladie auto-immune : série de cas et revue de la littérature
por: Frémont, G. Martin de, et al.
Publicado: (2023)

Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry
por: Salmon, J H, et al.
Publicado: (2015)

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
por: Le Gars, Mathieu, et al.
Publicado: (2022)

Humoral and Cellular Response after mRNA Vaccination in Nursing Homes: Influence of Age and of History of COVID-19
por: San Román, Jesús, et al.
Publicado: (2022)

The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)
por: Woldemeskel, Bezawit A, et al.
Publicado: (2021)

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
por: Ebinger, Joseph E., et al.
Publicado: (2021)

Humoral response to heterologous prime‐booster vaccination in heart transplant recipients aged 18–70 years primed with a viral vector SARS‐CoV‐2 vaccine
por: Tanner, Richard, et al.
Publicado: (2022)

The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose
por: Cohen, Idan, et al.
Publicado: (2023)

Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine
por: Grupping, Katrijn, et al.
Publicado: (2017)

SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
por: Richardson, Simone I., et al.
Publicado: (2022)

Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti–neutrophil cytoplasmic antibody vasculitis
por: Kant, Sam, et al.
Publicado: (2021)

Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab
por: Bacova, Barbora, et al.
Publicado: (2022)

Stratégies innovantes de vaccination anti-pneumococcique par rapport au schéma standard chez les patients atteints de vascularites associées aux ANCA recevant du rituximab : essai contrôlé randomisé multicentrique (PNEUMOVAS)
por: Terrier, B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_56qf5do4l4e2e9ao31o3snkfn7